Table 1.
Baseline characteristics of patients randomized in the two groups of treatment at the enrollment in the study.
| Low (10-12.5 μg/kg/day) | High (12.6-15 μg/kg/day) | |
|---|---|---|
| Number of patients | 36 | 36 |
| Sex Female/Male (%) | 61.8/38.2 | 57.6/42.4 |
| Gestational age (weeks) | 39 (37-41) | 40 (37-41) |
| Graffar Score | 13 (4-18) | 14 (4-18) |
| Age at diagnosis (days) | 13.36 ± 5.55 | 13.71 ± 6.85 |
| Moderate CH/Severe CH (%) | 63.6/36.4 | 66.7/33.3 |
| Adequate bone maturation/Retarded bone maturation (%) | 80/20 | 64/36 |
| Eutopic gland (%) | 46.2 | 25 |
| Ectopy gland (%) | 38.5 | 45.8 |
| Athyreosis (%) | 15.4 | 29.2 |
| TSH at diagnosis (mIU/l) | 296.0 ± 235.0 | 341.2 ± 279.7 |
| FT4 at diagnosis (ng/dl) | 0.55 ± 0.31 | 0.53 ± 0.34 |
| Initial L-T4 dose (μg/kg/day) | 11.69 ± 0.65 | 13.47 ± 0.84 |
Data are expressed as percentage, median and range or mean ± standard deviation.